Literature DB >> 10725066

Evaluation of filtration leucocytapheresis for use in the treatment of patients with rheumatoid arthritis.

Y Ueki1, S Yamasaki, Y Kanamoto, T Kawazu, M Yano, K Matsumoto, S Miyake, Y Tominaga, U Iwamoto, J Suemitsu, Y Matsuno, Y Sizume, Y Takenaka, K Eguchi.   

Abstract

OBJECTIVES: To evaluate the efficacy of filtration leucocytapheresis (LCP) for rheumatoid arthritis (RA).
METHODS: LCP was carried out three times, with 1 week separating each session, in 25 drug-resistant RA patients.
RESULTS: During each session, 96, 98, 61, 84 and 8% of the granulocytes, monocytes, lymphocytes, platelets and erythrocytes, respectively, that entered the LCP filter were removed. The number of granulocytes, monocytes and lymphocytes in the peripheral blood significantly decreased during each session of LCP. However, there was no significant decrease in the number of circulating blood cells during the study period. On average, 110 x 10(8) granulocytes, 5.23 x 10(8) monocytes, and 20.5 x 10(8) lymphocytes were removed during LCP therapy. Assessment of RA before and after LCP showed a substantial and rapid improvement in the tender joints counts, swollen joint counts, and patient's and physician's assessments. No adverse reactions or complications were noted. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels decreased following LCP, although the change in the latter parameter was statistically insignificant. The concentrations of serum albumin, gamma-globulin, IgG, IgM, CH50 and rheumatoid factor titres did not change during or after LCP. Careful analysis indicated that 16 of 25 patients with RA showed > or =20% improvement following LCP therapy.
CONCLUSIONS: Our results suggest that filtration LCP to remove leucocytes from the peripheral blood exerts an immunomodulatory effect in patients with RA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10725066     DOI: 10.1093/rheumatology/39.2.165

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  10 in total

1.  Leukocytapheresis (LCAP) for management of fulminant ulcerative colitis with toxic megacolon.

Authors:  Koji Sawada; Akimitsu Egashira; Kunio Ohnishi; Ken Fukunaga; Takeshi Kusaka; Takashi Shimoyama
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

2.  Leukocytapheresis for the treatment of refractory Henoch-Schönlein purpura resistant to both prednisolone and intravenous immunoglobulin therapy.

Authors:  Eishin Oki; Koji Tsugawa; Koichi Suzuki; Etsuro Ito; Hiroshi Tanaka
Journal:  Rheumatol Int       Date:  2008-03-12       Impact factor: 2.631

3.  Leukocytapheresis for the treatment of refractory Henoch-Schönlein purpura resistant to both prednisolone and intravenous immunoglobulin therapy.

Authors:  Eishin Oki; Koji Tsugawa; Koichi Suzuki; Etsuro Ito; Hiroshi Tanaka
Journal:  Rheumatol Int       Date:  2008-05-29       Impact factor: 2.631

4.  Diminished cytokine signalling against bacterial components in mononuclear leucocytes from ulcerative colitis patients after leukocytapheresis.

Authors:  K Mitsuyama; A Suzuki; S Matsumoto; N Tomiyasu; K Takaki; H Takedatsu; J Masuda; K Handa; K Harada; H Nishida; A Toyonaga; M Sata
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

5.  Leukocytapheresis for the treatment of refractory systemic-onset juvenile idiopathic arthritis.

Authors:  Hiroshi Tanaka; Koji Tsugawa; Tohru Nakahata; Koichi Suzuki; Etsuro Ito
Journal:  Clin Rheumatol       Date:  2006-03-25       Impact factor: 2.980

6.  Modulation of platelet aggregation responses by leukocytapheresis therapy in patients with active ulcerative colitis.

Authors:  Yuhki Yagi; Akira Andoh; Osamu Inatomi; Shigeki Bamba; Tomoyuki Tsujikawa; Yoshihide Fujiyama; Keiichi Mitsuyama; Takashi Yoshida
Journal:  J Gastroenterol       Date:  2006-06       Impact factor: 7.527

7.  Leukocytapheresis Therapy Improved Cholestasis in a Patient Suffering from Primary Sclerosing Cholangitis with Ulcerative Colitis.

Authors:  Minoru Itou; Keiichi Mitsuyama; Takumi Kawaguchi; Yoshinobu Okabe; Hideya Suga; Junya Masuda; Hiroshi Yamasaki; Kotaro Kuwaki; Eitaro Taniguchi; Masaru Harada; Osamu Tsuruta; Michio Sata
Journal:  Case Rep Gastroenterol       Date:  2009-04-15

8.  Exploring the feasibility of selective depletion of T lymphocyte subsets by whole blood immunoadsorption cytapheresis.

Authors:  M Belak; C R Valeri; D G Wright
Journal:  Clin Exp Immunol       Date:  2007-10-09       Impact factor: 4.330

9.  Partial remission of refractory RA after Adacolumn cytapheresis: a case report.

Authors:  L Bazzichi; T Giuliano; A Rossi; A Mazzoni; T Grazzini; F De Feo; C Giacomelli; F Scatena; S Bombardieri
Journal:  Rheumatol Int       Date:  2007-08-08       Impact factor: 2.631

10.  Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis--results of a randomized pilot trial.

Authors:  Jörg Emmrich; Sebastian Petermann; Dietrich Nowak; Ingolf Beutner; Peter Brock; Reinhard Klingel; Patrick Mausfeld-Lafdhiya; Stefan Liebe; Wolfgang Ramlow
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.